Aimei Health Technology Co., Ltd.

Aimei Health Technology Co., Ltd. announced that Director Julianne Huh resigned from her position effective June 24, 2026, citing personal reasons. Her resignation was accepted by the Board and was not due to any disagreement with the Company. Subsequently, on June 29, 2026, the Board approved and appointed Mr. Daniel Veikko Polvi as a new director. Mr. Polvi brings extensive experience in business management and consulting, having served as managing director of Shearwater Limited since May 2019.

Aimei Health Technology Co., Ltd. (AFJK) filed its 10-Q for the period ending March 31, 2026. The company reported a decrease in net income to $45,440 from $184,662 in the prior year's quarter, primarily due to lower interest income from its trust account. Operating costs also saw a reduction. Total assets grew slightly, while liabilities and shareholders' deficit also increased.

Aimei Health Technology Co., Ltd. has extended the termination date for its initial business combination by one month to July 6, 2026, by depositing $34,330.96 into its trust account. In connection with this extension, the company issued an unsecured promissory note of the same amount to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc. The note is interest-free and can be converted into private units prior to the business combination.

Aimei Health Technology Co., Ltd. received a notice from Nasdaq on May 19, 2026, indicating non-compliance with listing rules due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The report was due on May 15, 2026. While there is no immediate impact on the company's stock listing, failure to regain compliance could lead to delisting. The company has 60 days to file the report or submit a compliance plan and is diligently working to complete the filing.

Aimei Health Technology Co., Ltd. (AFJK) announced that it received a notice from Nasdaq on May 19, 2026, indicating non-compliance with Listing Rule 5250(c)(1). This non-compliance stems from the company's delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, which was due on May 15, 2026. While there is no immediate impact on the trading of its securities, AFJK has 60 calendar days to either file the report or submit a plan to regain compliance, with potential delisting if compliance is not restored. The company stated it is working diligently to file the report and expects to regain compliance.

Aimei Health Technology Co., Ltd. extended the period to consummate its initial business combination by one month, from May 6, 2026, to June 6, 2026. This eighteenth extension was facilitated by an aggregate $34,330.96 deposit into the trust account for public shareholders. In connection with this, the company issued an unsecured promissory note for $34,330.96 to Aimei Health Ltd and United Hydrogen Group Inc., with each contributing $17,165.48. The note does not bear interest and is convertible into private units at $10.00 per unit.

Aimei Health Technology Co., Ltd. (AFJK), a SPAC, is progressing with its proposed business combination with United Hydrogen Group Inc., which was initially agreed upon in June 2024 and approved by Aimei Health shareholders in November 2025. However, the closing is currently pending United Hydrogen obtaining necessary approvals from the China Securities Regulatory Commission (CSRC), causing delays. The deadline for completing the business combination has been extended multiple times, most recently to May 6, 2026, with the Sponsor and United Hydrogen making monthly deposits. The company also highlighted significant legal and operational risks associated with potential business combinations involving PRC-based companies, including United Hydrogen, and stated it will not acquire companies operating through VIEs.

Aimei Health Technology Co., Ltd. (AFJK) received a notice from Nasdaq on April 17, 2026, indicating non-compliance with listing rules due to the failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report was due on March 31, 2026. While this notice has no immediate effect on the company's listing or trading, AFJK faces potential delisting if it fails to regain compliance. The company has 60 calendar days to file the report or submit a plan to Nasdaq, with a possible extension of up to 180 days from the original due date. Aimei Health is working diligently to complete and file the Annual Report and expects to regain compliance.

Aimei Health Technology Co., Ltd. announced it received a notice from Nasdaq on April 17, 2026, indicating non-compliance with listing rules due to its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report was due on March 31, 2026. The company now has 60 calendar days to either file the Annual Report or submit a plan to regain compliance, with a potential extension up to 180 days from the original due date. Failure to resolve this deficiency could result in the delisting of the company's securities from Nasdaq.

Aimei Health Technology Co., Ltd. (AFJK) has announced a one-month extension for the consummation of its initial business combination, moving the new termination date to May 6, 2026. This marks the seventeenth such extension, indicating a prolonged process in finalizing its merger. To facilitate this extension, an aggregate of $34,330.96 was deposited into the company's trust account for public shareholders. The funding was provided through an unsecured promissory note issued to its Sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., the target company, ensuring the SPAC maintains its public listing while it continues to pursue the deal.